Nuveen Asset Management LLC bought a new position in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 197,751 shares of the biotechnology company’s stock, valued at approximately $16,686,000. Nuveen Asset Management LLC owned about 1.00% of Enanta Pharmaceuticals as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. Point72 Asset Management L.P. purchased a new position in Enanta Pharmaceuticals during the second quarter worth approximately $34,000. Bank of Montreal Can boosted its position in Enanta Pharmaceuticals by 198.3% during the second quarter. Bank of Montreal Can now owns 2,300 shares of the biotechnology company’s stock worth $194,000 after purchasing an additional 1,529 shares in the last quarter. Jane Street Group LLC purchased a new position in Enanta Pharmaceuticals during the second quarter worth approximately $208,000. GAM Holding AG purchased a new position in Enanta Pharmaceuticals during the second quarter worth approximately $215,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Enanta Pharmaceuticals during the second quarter worth approximately $224,000. Hedge funds and other institutional investors own 88.57% of the company’s stock.
A number of equities analysts have issued reports on ENTA shares. ValuEngine downgraded Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, September 26th. JPMorgan Chase & Co. downgraded Enanta Pharmaceuticals from a “neutral” rating to an “underweight” rating and lowered their price target for the stock from $86.00 to $57.00 in a research report on Thursday, September 26th. Berenberg Bank set a $130.00 target price on Enanta Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, September 18th. Zacks Investment Research cut Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 12th. Finally, BidaskClub raised Enanta Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, September 21st. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $97.20.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $0.33 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.27. Enanta Pharmaceuticals had a return on equity of 15.16% and a net margin of 29.22%. The business had revenue of $44.40 million during the quarter, compared to analysts’ expectations of $46.98 million. During the same quarter in the prior year, the firm earned $0.97 earnings per share. The business’s revenue was down 22.5% compared to the same quarter last year. As a group, equities analysts forecast that Enanta Pharmaceuticals Inc will post 2.39 EPS for the current fiscal year.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Featured Article: Cost of Capital Explained
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.